329 related articles for article (PubMed ID: 24491438)
1. Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms.
Yang Y; Schmitz R; Mitala J; Whiting A; Xiao W; Ceribelli M; Wright GW; Zhao H; Yang Y; Xu W; Rosenwald A; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Wiestner A; Kruhlak MJ; Iwai K; Bernal F; Staudt LM
Cancer Discov; 2014 Apr; 4(4):480-93. PubMed ID: 24491438
[TBL] [Abstract][Full Text] [Related]
2. Identification and molecular analysis of RNF31 Q622H germline polymorphism.
Nakazawa S; Mamiya R; Kawabata-Iwakawa R; Oikawa D; Kaira K; Tokunaga F; Nobusawa S; Sato Y; Sasaki A; Yajima T; Shirabe K
Oncol Lett; 2022 Nov; 24(5):394. PubMed ID: 36276481
[TBL] [Abstract][Full Text] [Related]
3. Germline polymorphisms in RNF31 regulate linear ubiquitination and oncogenic signaling.
Grumati P; Dikic I
Cancer Discov; 2014 Apr; 4(4):394-6. PubMed ID: 24706658
[TBL] [Abstract][Full Text] [Related]
4. The paracaspase MALT1 cleaves the LUBAC subunit HOIL1 during antigen receptor signaling.
Douanne T; Gavard J; Bidère N
J Cell Sci; 2016 May; 129(9):1775-80. PubMed ID: 27006117
[TBL] [Abstract][Full Text] [Related]
5. LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells.
Jo T; Nishikori M; Kogure Y; Arima H; Sasaki K; Sasaki Y; Nakagawa T; Iwai F; Momose S; Shiraishi A; Kiyonari H; Kagaya N; Onuki T; Shin-Ya K; Yoshida M; Kataoka K; Ogawa S; Iwai K; Takaori-Kondo A
Blood; 2020 Aug; 136(6):684-697. PubMed ID: 32325488
[TBL] [Abstract][Full Text] [Related]
6. Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.
Yang Y; Kelly P; Shaffer AL; Schmitz R; Yoo HM; Liu X; Huang DW; Webster D; Young RM; Nakagawa M; Ceribelli M; Wright GW; Yang Y; Zhao H; Yu X; Xu W; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza L; Staudt LM
Cancer Cell; 2016 Apr; 29(4):494-507. PubMed ID: 27070702
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.
Ferch U; Kloo B; Gewies A; Pfänder V; Düwel M; Peschel C; Krappmann D; Ruland J
J Exp Med; 2009 Oct; 206(11):2313-20. PubMed ID: 19841089
[TBL] [Abstract][Full Text] [Related]
8. Molecular Determinants of Scaffold-induced Linear Ubiquitinylation of B Cell Lymphoma/Leukemia 10 (Bcl10) during T Cell Receptor and Oncogenic Caspase Recruitment Domain-containing Protein 11 (CARD11) Signaling.
Yang YK; Yang C; Chan W; Wang Z; Deibel KE; Pomerantz JL
J Biol Chem; 2016 Dec; 291(50):25921-25936. PubMed ID: 27777308
[TBL] [Abstract][Full Text] [Related]
9. Cellular and Mathematical Analyses of LUBAC Involvement in T Cell Receptor-Mediated NF-κB Activation Pathway.
Oikawa D; Hatanaka N; Suzuki T; Tokunaga F
Front Immunol; 2020; 11():601926. PubMed ID: 33329596
[TBL] [Abstract][Full Text] [Related]
10. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
11. A catalytic-independent role for the LUBAC in NF-κB activation upon antigen receptor engagement and in lymphoma cells.
Dubois SM; Alexia C; Wu Y; Leclair HM; Leveau C; Schol E; Fest T; Tarte K; Chen ZJ; Gavard J; Bidère N
Blood; 2014 Apr; 123(14):2199-203. PubMed ID: 24497531
[TBL] [Abstract][Full Text] [Related]
12. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.
Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Mason NJ
Clin Cancer Res; 2011 Jul; 17(14):4661-71. PubMed ID: 21610150
[TBL] [Abstract][Full Text] [Related]
13. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
[TBL] [Abstract][Full Text] [Related]
14. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.
Kloo B; Nagel D; Pfeifer M; Grau M; Düwel M; Vincendeau M; Dörken B; Lenz P; Lenz G; Krappmann D
Proc Natl Acad Sci U S A; 2011 Jan; 108(1):272-7. PubMed ID: 21173233
[TBL] [Abstract][Full Text] [Related]
15. Biophysical and biological evaluation of optimized stapled peptide inhibitors of the linear ubiquitin chain assembly complex (LUBAC).
Aguilar-Alonso F; Whiting AL; Kim YJ; Bernal F
Bioorg Med Chem; 2018 Mar; 26(6):1179-1188. PubMed ID: 29246782
[TBL] [Abstract][Full Text] [Related]
16. SHARPIN is a component of the NF-κB-activating linear ubiquitin chain assembly complex.
Tokunaga F; Nakagawa T; Nakahara M; Saeki Y; Taniguchi M; Sakata S; Tanaka K; Nakano H; Iwai K
Nature; 2011 Mar; 471(7340):633-6. PubMed ID: 21455180
[TBL] [Abstract][Full Text] [Related]
17. LUBAC-mediated linear ubiquitination in tissue homeostasis and disease.
Sasaki K; Iwai K
J Biochem; 2023 Jul; 174(2):99-107. PubMed ID: 37279649
[TBL] [Abstract][Full Text] [Related]
18. Targeting BCL10 by small peptides for the treatment of B cell lymphoma.
Bao W; Sun C; Sun X; He M; Yu H; Yan W; Wen F; Zhang L; Yang C
Theranostics; 2020; 10(25):11622-11636. PubMed ID: 33052237
[No Abstract] [Full Text] [Related]
19. USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.
Wu Y; Gu H; Bao Y; Lin T; Wang Z; Gu D; Shen H; Xian H; Fan Y; Mao R
Cell Biochem Funct; 2022 Jun; 40(4):379-390. PubMed ID: 35411950
[TBL] [Abstract][Full Text] [Related]
20. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.
Ceribelli M; Kelly PN; Shaffer AL; Wright GW; Xiao W; Yang Y; Mathews Griner LA; Guha R; Shinn P; Keller JM; Liu D; Patel PR; Ferrer M; Joshi S; Nerle S; Sandy P; Normant E; Thomas CJ; Staudt LM
Proc Natl Acad Sci U S A; 2014 Aug; 111(31):11365-70. PubMed ID: 25049379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
